Personal-Use Self-monitoring Blood Glucose Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Personal-Use Self Monitoring Blood Glucose Devices Market Report is Segmented by Component (Glucometer Devices, Test Strips, and More), Technology (SMBG (Capillary), Continuous Glucose Monitoring (Personal), and More), Connectivity (Wired / USB, NFC, and More), End-User (Home-Care / Personal and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Personal-Use Self-monitoring Blood Glucose Devices Market Size and Share

Personal-Use Self-monitoring Blood Glucose Devices Market (2025 - 2030)
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Personal-Use Self-monitoring Blood Glucose Devices Market with other markets in Healthcare Industry

Personal-Use Self-monitoring Blood Glucose Devices Market Analysis by Mordor Intelligence

The personal-use self-monitoring blood glucose devices market size reached USD 4.40 billion in 2025 and is forecast to touch USD 6.10 billion by 2030, advancing at a 6.75% CAGR during the period. The expansion reflects the compound effect of rising diabetes prevalence, population aging, and steady reimbursement gains for connected meters. Continuous sensor innovation, smartphone integration, and over-the-counter (OTC) clearances broaden the addressable base beyond insulin-dependent patients, while real-time analytics improve therapeutic decision-making. Growth also benefits from expanding wellness adoption among non-diabetic consumers and sustained venture funding that accelerates miniaturized, low-power designs. Competitive intensity remains moderate but is sharpening as scale players link glucose data with automated insulin delivery, digital coaching, and generative AI platforms.

Key Report Takeaways

  • By component, test strips led with 65.25% of personal-use self-monitoring blood glucose devices market share in 2024, whereas glucometer devices are set to post the fastest 9.25% CAGR to 2030.
  • By technology, self-monitoring blood glucose accounted for 35.53% revenue share in 2024, while continuous glucose monitoring is poised to rise at a 12.35% CAGR.
  • By connectivity, Bluetooth commanded 43.82% revenue share in 2024; near-field communication is projected to climb at an 11.26% CAGR through 2030.
  • By end-user, the home-care segment represented 88.82% of industry revenue in 2024, while sports and wellness users are forecast to expand at 11.62% CAGR.
  • By geography, North America held 42.82% revenue share in 2024, yet Asia-Pacific is on track for the quickest 12.62% CAGR to 2030.

Segment Analysis

By Component: Consumables Continue to Anchor Revenue

Test strips captured 65.25% of the personal-use self-monitoring blood glucose devices market in 2024, preserving a high-margin replenishment stream that underwrites manufacturer cash flows. Devices, however, are registering the quickest 9.25% CAGR as users pivot to integrated, sensor-rich platforms that lower per-reading cost over time. Longer wear sensors such as Dexcom G7 15-Day demonstrate how hardware upgrades decrease monthly spend and improve convenience. Accessories—from lancet drums to smartphone cradles—command modest but rising revenue as connectivity and comfort influence brand choice.

Glucometer innovation now targets single-platform ecosystems that pair proprietary sensors with AI-driven apps. Abbott’s FreeStyle Libre 2 Plus, the first U.S. CGM to link directly with automated insulin delivery, illustrates the hardware-software convergence reshaping the personal-use self-monitoring blood glucose devices market. Vendors also trial reusable optical readers designed to leverage strip-free photonics, potentially compressing consumable demand. While strips remain dominant, incremental sensor advances steadily shift revenue weight toward durable equipment and cloud subscriptions.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Technology: Continuous Monitoring Disrupts SMBG Hegemony

Self-monitoring blood glucose still holds 35.53% share, anchored by affordability and clinician familiarity. Nevertheless, continuous sensors are outpacing at 12.35% CAGR because real-time trend data reduce hypoglycemia risk and support dose titration. Randomized studies in primary care show CGM users achieving HbA1c drops of 1.3 percentage points versus 0.8 points for finger-stick cohorts. Non-invasive optical prototypes demonstrate accelerating accuracy gains, aided by machine-learning spectroscopic algorithms.

Technology suppliers bundle sensors with telehealth dashboards, broadening clinical oversight and unlocking insurer value-based payments. Medtronic’s Simplera disposable CGM, half the size of its predecessor, shows how form-factor reductions drive comfort and adoption. As reimbursement spreads and component costs fall, CGM looks set to erode SMBG leadership across the personal-use self-monitoring blood glucose devices market.

By Connectivity: Bluetooth Reigns While NFC Accelerates

Bluetooth retained 43.82% revenue share in 2024, benefitting from universal smartphone support and established pairing stacks. Near-field communication, however, is projected to grow 11.26% annually because it permits tap-to-scan uploads without user configuration. NFC chips also consume less power, extending sensor life and fostering fully disposable designs. USB and proprietary cables linger for clinical download stations but fade in consumer channels.

Connectivity now underpins analytics differentiation. Dexcom recently launched the first glucose biosensing generative-AI platform on Google Vertex AI, a move that demands stable, low-latency data links. NFC’s simplicity supports elderly users and emerging-market customers who rely on entry-level Android phones, expanding penetration of the personal-use self-monitoring blood glucose devices market.

Market Share
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End-User: Home-Care Dominates Yet Wellness Surges

Home-care applications represented 88.82% of revenue in 2024, reflecting the day-to-day nature of diabetes self-management. Retail OTC approvals now allow walk-in purchase, bolstering household adoption. Simultaneously, sports and wellness users are forecast for an 11.62% CAGR as athletes and weight-loss seekers adopt CGMs to fine-tune diet and training. A multi-armed study on non-diabetic Indians using Ultrahuman’s platform illustrated how real-time glucose curves encourage healthier meal choices.

Mainstream media coverage has normalized CGM for metabolic awareness, though data literacy gaps persist. Manufacturers counter by embedding color-coded insights and automated food logging. Wellness adoption thus diversifies revenue and creates a preventive front door for the personal-use self-monitoring blood glucose devices market.

Geography Analysis

North America led the personal-use self-monitoring blood glucose devices market with 42.82% revenue share in 2024 on the back of payer funding, early tech uptake, and robust distribution networks. Medicare’s expanded coverage and successive private-payer updates have widened eligibility for continuous sensors, spurring double-digit unit growth. The U.S. FDA’s friendly stance toward OTC clearances further enlarges the consumer funnel and shortens go-to-market cycles. Canada mirrors these trends, advancing national reimbursement pilots for flash sensors.

Asia-Pacific is projected to log a 12.62% CAGR through 2030 as high prevalence converges with rising middle-class disposable income. China’s digital health programs demonstrate that integrated platforms can trim fasting glucose by 1.68% and HbA1c by 0.45 points among engaged users. India’s uptake of point-of-care HbA1c screening, with an ICUR of just USD 185.10/QALY in rural settings, underscores economic viability. Government initiatives to localize sensor assembly are also likely to shrink end-user prices, fuelling further expansion of the personal-use self-monitoring blood glucose devices market.

Europe maintains stable mid-single-digit growth, underpinned by national funding steps such as Norway’s 2023 decision to reimburse sensor-based monitors. The EU’s Medical Device Regulation harmonizes safety benchmarks, favoring firms with rigorous quality systems. Meanwhile, Latin America and Middle East-Africa show rising incidence but adoption lags due to cost and limited payer coverage. Nevertheless, philanthropic procurement and telehealth pilots in Gulf Cooperation Council states foreshadow incremental upside.

Growth Rate
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Competition centers on technology leadership, integrated ecosystems, and regulatory agility. Abbott, Dexcom, and Roche collectively anchor the top tier, each leveraging data platforms to lock in users. Abbott’s August 2024 agreement with Medtronic links FreeStyle Libre sensors with automated insulin pumps, broadening closed-loop care. Dexcom counters through AI-driven insight engines that personalize coaching and flag glycemic excursions in real time.

Mid-cap players pursue white-space. Glucotrack advanced an implantable monitor through first-in-human trials, potentially eliminating external wearables. Tandem Diabetes Care signed a June 2025 pact with Abbott to incorporate dual glucose-ketone sensing into its automated delivery portfolio. Such alliances consolidate data streams, complicate entrant differentiation, and heighten switching costs in the personal-use self-monitoring blood glucose devices market.

Regulatory standards raise technical hurdles. The May 2025 FDA rule (21 CFR 862.1355) codified accuracy and cybersecurity criteria for integrated systems, prompting heavy investment in quality assurance. Vendors that meet these bars gain first-mover market access, while laggards risk reimbursement exclusion. As platform convergence intensifies, channel leverage and data-analytics capability are expected to determine share shifts over the next five years.

Personal-Use Self-monitoring Blood Glucose Devices Industry Leaders

  1. LifeScan Inc.

  2. Arkray Inc.

  3. Ascensia Diabetes Care Holdings AG

  4. F. Hoffmann-La Roche AG

  5. Abbott Laboratories

  6. *Disclaimer: Major Players sorted in no particular order
Personal-Use Self-monitoring Blood Glucose Devices Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • January 2025: PT Diagnostics introduced the A1CNow SELF CHECK in the UK, enabling individuals to monitor diabetes in just five minutes at home.
  • June 2024: Abbott secured FDA clearance for Lingo, an OTC CGM aimed at both diabetes and general wellness audiences.

Table of Contents for Personal-Use Self-monitoring Blood Glucose Devices Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Diabetes Prevalence & Ageing Population
    • 4.2.2 Smartphone-Linked Smart Meters Gain Reimbursement Traction
    • 4.2.3 Expansion Of Continuous & Flash GM Into Type-2 Pre-Diabetes
    • 4.2.4 OTC Approval Of Non-Invasive Optical Meters
    • 4.2.5 Wellness Wearables Drive Adoption By Non-Diabetics
  • 4.3 Market Restraints
    • 4.3.1 High Lifetime Cost Of Consumables (Strips / Sensors)
    • 4.3.2 Accuracy Gaps Vs. Lab Reference In Tropical Climates
    • 4.3.3 Cyber-Security & Data-Privacy Regulations Tighten
  • 4.4 Supply-Chain Analysis
  • 4.5 Technological Outlook
  • 4.6 Porter's Five Forces
    • 4.6.1 Bargaining Power of Suppliers
    • 4.6.2 Bargaining Power of Buyers
    • 4.6.3 Threat of New Entrants
    • 4.6.4 Threat of Substitutes
    • 4.6.5 Intensity of Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Component
    • 5.1.1 Glucometer Devices
    • 5.1.2 Test Strips
    • 5.1.3 Lancets
    • 5.1.4 Accessories
  • 5.2 By Technology
    • 5.2.1 SMBG (Capillary)
    • 5.2.2 Continuous Glucose Monitoring (Personal)
    • 5.2.3 Non-Invasive Optical Monitoring
  • 5.3 By Connectivity
    • 5.3.1 Wired / USB
    • 5.3.2 Bluetooth / BLE
    • 5.3.3 NFC
  • 5.4 By End-User
    • 5.4.1 Home-Care / Personal
    • 5.4.2 Sports & Wellness Users
  • 5.5 Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
    • 6.3.1 Abbott Laboratories
    • 6.3.2 F. Hoffmann-La Roche
    • 6.3.3 LifeScan Inc
    • 6.3.4 Arkray
    • 6.3.5 Ascensia Diabetes Care
    • 6.3.6 AgaMatrix
    • 6.3.7 Bionime
    • 6.3.8 ACON Laboratories
    • 6.3.9 Medisana
    • 6.3.10 Rossmax
    • 6.3.11 Dexcom, Inc.
    • 6.3.12 Medtronic plc
    • 6.3.13 Insulet
    • 6.3.14 Senseonics
    • 6.3.15 Omron Healthcare
    • 6.3.16 i-SENS
    • 6.3.17 Ypsomed AG
    • 6.3.18 Terumo Corporation
    • 6.3.19 Nova Biomedical
    • 6.3.20 ForaCare
    • 6.3.21 DarioHealth
    • 6.3.22 Trividia Health
    • 6.3.23 Becton Dickinson
    • 6.3.24 iHealth Labs

7. Market Opportunities & Future Outlook

  • 7.1 White-Space & Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Personal-Use Self-monitoring Blood Glucose Devices Market Report Scope

Personal use self-monitoring of blood glucose is an approach used by diabetic patients to measure their blood sugar level themselves using a glucometer, test strips, and lancets at home setting. Based on the readings, patients can adjust or check the effect of their treatment.

The self-monitoring blood glucose device market is segmented into components and geography. By component, the market is further sub-segmented into Glucometer Devices, Test Strips, and Lancet. By Geography, the market is subsegmented into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America. The report offers the value (in USD) for the above segments.

By Component Glucometer Devices
Test Strips
Lancets
Accessories
By Technology SMBG (Capillary)
Continuous Glucose Monitoring (Personal)
Non-Invasive Optical Monitoring
By Connectivity Wired / USB
Bluetooth / BLE
NFC
By End-User Home-Care / Personal
Sports & Wellness Users
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Component
Glucometer Devices
Test Strips
Lancets
Accessories
By Technology
SMBG (Capillary)
Continuous Glucose Monitoring (Personal)
Non-Invasive Optical Monitoring
By Connectivity
Wired / USB
Bluetooth / BLE
NFC
By End-User
Home-Care / Personal
Sports & Wellness Users
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current size of the personal-use self-monitoring blood glucose devices market?

The market stands at USD 4.40 billion in 2025 and is projected to reach USD 6.10 billion by 2030.

Which component category generates the most revenue?

Test strips lead with 65.25% market share in 2024, anchoring recurring revenue.

How fast is continuous glucose monitoring (CGM) growing?

CGM is advancing at a 12.35% CAGR through 2030, the quickest pace among technology segments.

Which region is expanding the fastest?

Asia-Pacific is forecast to grow at a 12.62% CAGR on the back of rising diabetes prevalence and healthcare investments.

What recent regulatory move is boosting consumer adoption?

The FDA’s 2024 OTC clearance of devices like Dexcom’s Stelo and Abbott’s Lingo removed prescription barriers and widened access.

Personal-Use Self-monitoring Blood Glucose Devices Market Report Snapshots